View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2019	Mar. 16, 2020
Document Information [Line Items]
Entity Registrant Name	XBiotech Inc.
Entity Central Index Key	0001626878
Trading Symbol	xbit
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		28,852,927
Entity Public Float	$ 581,565,527
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, no par value

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 714,594	$ 15,823
Prepaid expenses and other current assets	1,669	1,193
Total current assets	716,263	17,016
Escrow receivable	75,000
Deferred tax asset	443
Property and equipment, net	25,171	27,329
Total assets	816,877	44,345
Current liabilities:
Accounts payable	2,149	1,653
Accrued expenses	4,180	1,291
Contract liabilities	4,500
Other taxes payable	49,361
Total current liabilities	60,190	2,944
Long-term liabilities:
Deferred rent		3
Income tax payable – non-current	1,056
Total liabilities	61,246	2,947
Shareholders’ equity:
Preferred Stock, no par value, unlimited shares authorized, no shares outstanding	0	0
Common stock, no par value, unlimited shares authorized, 41,519,633 and 35,899,772 shares outstanding at December 31, 2019 and December 31, 2018, respectively	324,808	279,353
Accumulated other comprehensive loss	(106)	(255)
Retained earnings	430,929	(237,700)
Total shareholders’ equity	755,631	41,398
Total liabilities and shareholders’ equity	$ 816,877	$ 44,345

Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, no par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares authorized	Unlimited	Unlimited
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares outstanding (in shares)	41,519,633	35,899,772

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating expenses:
Research and development	$ 24,090	$ 15,725	$ 26,424
General and administrative	7,143	5,269	7,635
Total operating expenses	31,233	20,994	34,059
Loss from operations	(31,233)	(20,994)	(34,059)
Other income (loss):
Interest income	564	400	354
Gain from Janssen Transaction	750,000
Other income	10	4
Foreign exchange gain (loss)	(888)	(548)	555
Total other income (loss)	749,686	(144)	909
Income before income taxes	718,453	(21,138)	(33,150)
Provision for income taxes	(49,824)
Net income (loss)	$ 668,629	$ (21,138)	$ (33,150)
Net income (loss) per share—basic (in dollars per share)	$ 17.17	$ (0.59)	$ (0.95)
Shares used to compute basic net income (loss) per share (in shares)	38,945,468	35,804,304	34,875,814
Net income (loss) per share—diluted (in dollars per share)	$ 14.44	$ (0.59)	$ (0.95)
Shares used to compute diluted net income (loss) per share (in shares)	46,319,457	35,804,304	34,875,814

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net income (loss)	$ 668,629	$ (21,138)	$ (33,150)
Foreign currency translation adjustment	149	513	(825)
Comprehensive income (loss)	$ 668,778	$ (20,625)	$ (33,975)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock Including Additional Paid in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016	32,628
Balance at Dec. 31, 2016	$ 242,419	$ 57	$ (183,412)	$ 59,064
Net income (loss)			(33,150)	(33,150)
Foreign currency translation adjustment		(825)		(825)
Issuance of common stock, net of issuance cost (in shares)	2,521
Issuance of common stock, net of issuance cost	$ 32,620			32,620
Issuance of common stock under stock option plan (in shares)	290
Issuance of common stock under stock option plan	$ 818			818
Share-based compensation expense	1,635			1,635
Share-based compensation expense	$ 1,635			1,635
Balance (in shares) at Dec. 31, 2017	35,439
Balance at Dec. 31, 2017	$ 277,492	(768)	(216,562)	60,162
Net income (loss)			(21,138)	(21,138)
Foreign currency translation adjustment		513		513
Issuance of common stock, net of issuance cost (in shares)	300
Issuance of common stock, net of issuance cost
Issuance of common stock under stock option plan (in shares)	161
Issuance of common stock under stock option plan	$ 401			401
Share-based compensation expense	1,660			1,660
Subscription receivable	(200)			(200)
Share-based compensation expense	$ 1,660			1,660
Balance (in shares) at Dec. 31, 2018	35,900
Balance at Dec. 31, 2018	$ 279,353	(255)	(237,700)	41,398
Net income (loss)			668,629	668,629
Foreign currency translation adjustment		149		149
Issuance of common stock, net of issuance cost (in shares)	4,848
Issuance of common stock, net of issuance cost	$ 38,062			38,062
Issuance of common stock under stock option plan (in shares)	771
Issuance of common stock under stock option plan	$ 3,835			3,835
Share-based compensation expense	3,358			3,358
Subscription receivable	(102)			(102)
Share-based compensation expense	3,358			3,358
Collection of stock subscription receivable	$ 302			302
Balance (in shares) at Dec. 31, 2019	41,519
Balance at Dec. 31, 2019	$ 324,808	$ (106)	$ 430,929	$ 755,631

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities
Net income (loss)	$ 668,629	$ (21,138)	$ (33,150)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,361	2,433	1,484
Share-based compensation expense	3,358	1,660	1,750
Gain from Janssen Transaction	(675,000)
Amount Held in Escrow	(75,000)
Deferred Tax Asset	(444)
Other non-cash adjustments			401
Changes in operating assets and liabilities:
Prepaid expenses and other current	(472)	372	1,041
Accounts payable	496	(78)	(2,700)
Accrued expenses	2,888	229	(2,470)
Contract liabilities	4,500
Other taxes payable	49,361
Deferred rent	(3)	(15)	(5)
Income tax payable – non-current	1,056
Net cash used in operating activities	(18,270)	(16,537)	(33,649)
Investing activities
Purchase of property and equipment	(204)	(122)	(1,405)
Cash received from Janssen Transaction	675,000
Net cash provided by investing activities	674,796	(122)	(1,405)
Financing activities
Issuance of common stock and warrants, net	38,062		32,620
Issuance of common stock under stock option plan	3,732	201	703
Collection of subscription receivable	302
Net cash provided by financing activities	42,096	201	33,323
Effect of foreign exchange rate on cash and cash equivalents	149	513	(825)
Net change in cash and cash equivalents	698,771	(15,945)	(2,556)
Cash and cash equivalents, beginning of period	15,823	31,768	34,324
Cash and cash equivalents, end of period	714,594	15,823	31,768
Supplemental Information:
Subscription receivable		$ 200

Note 1 - Organization	12 Months Ended
Note 1 - Organization	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization XBiotech Inc. (XBiotech or the Company) was incorporated in Canada on March 22, 2005. XBiotech USA, Inc., a wholly-owned subsidiary of the Company, was incorporated in Delaware, United States in November 2007. XBiotech Switzerland AG, a wholly-owned subsidiary of the Company, was incorporated in Zug, Switzerland in August 2010. XBiotech Japan K.K., a wholly-owned subsidiary of the Company, was incorporated in Tokyo, Japan in March 2013. XBiotech Germany GmbH, a wholly-owned subsidiary of the Company, was incorporated in Germany in January 2014. The Company’s headquarters are located in Austin, Texas. Since its inception, XBiotech has focused on advancing technology to rapidly identify and clone antibodies from individuals that have resistance to disease. At the heart of the Company is a proprietary technical knowhow to translate natural human immunity into therapeutic product candidates. In 2005, the Company began to develop a new framework for commercial manufacturing, using technology that required less capital, fewer operators and provided greater flexibility than standard industry practices. With the manufacturing capability to produce its True Human ™ antibody therapy, in 2010, the Company began a clinical trial program. The first clinical trial program at MD Anderson Cancer Center began treating the sickest cancer patients irrespective of tumor type. Soon thereafter, the Company used the same antibody therapy in various clinical studies at treatment centers around the United States (U.S.) and abroad to investigate the antibody effect in patients that had vascular disease, leukemia, type 2 diabetes, psoriasis or acne. The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $714.6 million at December 31, 2019, will enable the Company to achieve several major inflection points, including potential new clinical studies with our lead product candidate. We expect to have sufficient cash through one year from the report issuance date.

Note 2 - Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Significant Accounting Policies

Basis of Presentation

These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (US GAAP).

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

Prior to its initial public offering on

April 15, 2015,

the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors determined the estimated fair value of the Company’s common stock based on a number of objective and subjective factors, including the prices at which the Company sold shares of its common stock to

third

parties and external market conditions affecting the biotechnology industry sector. After the initial public offering, the fair market value is calculated by using the closing price of the Company’s common stock as reported by NASDAQ.

Research and Development Costs

All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with

alternative future use are expensed as incurred as research and development costs.

Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.

Income Taxes

The Company makes estimates and judgments in determining the need for a provision for income taxes, including the estimation of its taxable income or loss for the full fiscal year. The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating losses and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets certain deferred tax assets with a valuation allowance. The Company

may

in the future determine that certain deferred tax assets more-likely-than-

not

be realized, in which case the Company will reduce its valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, the Company

may

recognize a benefit from income taxes in its statement of operations in that period.

Income taxes are recorded in accordance with ASC

740,

Accounting for Income Taxes

(“ASC

740”

), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than

not

that some or all of the deferred tax assets will

not

be realized.

ASC

740

clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position

may

be recognized when it is more likely than

not

that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense.

Share-Based Compensation

The Company accounts for its share-based compensation awards in accordance with ASC Topic

718,

Compensation-Stock Compensation

(“ASC

718”

). ASC

718,

which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, the Company recognizes share-based compensation expense, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis.

Share-based compensation expense recognized for the years ended

December 31, 2019,

2018

and

2017

was included in the following line items on the Consolidated Statements of Operations (in thousands).

	Year Ended December 31,
	2019		2018		2017

Research and development	$	1,635	$	696	$	413
General and administrative		1,723		964		2,063

Total share-based compensation expense	$	3,358	$	1,660	$	2,476

The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions:

	Year Ended December 31,
	2019			2018			2017
Weighted-average grant date fair value per share		$9.36			$4.32			$4.85
Expected volatility	80%	-	97%	67%	-	80%	65%	-	67%
Risk-free interest rate	1.41%	-	2.64%	2.38%	-	3.12%	1.83%	-	2.41%
Expected life (in years)	5.38	–	10	1	–	10	5.38	–	10
Dividend yield		—			—			—

Due to the adoption of ASU

No.

2016

09,

“Stock Compensation” on

January 1, 2017,

the Company accounts for forfeitures as they occur rather than on an estimated basis.

Cash and Cash Equivalents

The Company considers highly liquid investments with a maturity of

days or less when purchased to be cash equivalents. Cash and cash equivalents consisted primarily of cash on deposit in U.S., German, Swiss and Canadian banks. Cash and cash equivalents are stated at cost which approximates fair value.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any

one

financial institution. These amounts at times

may

exceed federally insured limits. The Company has

not

experienced any credit losses in such accounts and does

not

believe it is exposed to any significant credit risk on these funds. The Company has

off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Fair Value Measurements

The Company follows ASC Topic

820,

Fair Value Measurements and Disclosures

, which establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market date (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of

three

levels:

	•	Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities.

	•	Level 2—Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

•

Level

3—Unobservable

inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

December 31, 2019

and

2018,

the Company did

have any assets or liabilities that are measured at fair value on a recurring basis. The carrying amounts reflected in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at

December 31, 2019

and

2018,

due to their short-term nature.

Property and Equipment

Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are

not

depreciated, using the straight line method. The useful lives are as follows:

• Furniture and fixtures	7 years

• Office equipment	5 years

• Scientific equipment	5 years

• Vehicles	5 years

• Mobile facility	27.5 years

• Building	39 years

Costs of major additions and betterments are capitalized; maintenance and repairs, which do

not

improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.

Impairment of Long-Lived Assets

The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic

360,

Property, Plant and Equipment

. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset

may

not

be recovered. Recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has

not

recognized any impairment through

December 31, 2019.

Foreign Currency Transactions

Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled.

Comprehensive Income (Loss)

ASC Topic

220,

Comprehensive Income

, requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.

Segment and Geographic Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as

one

operating segment. Substantially all of the Company’s operations are in the U.S. geographic segment.

Net Income/Loss per Share

Net income/loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income/loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method.

Subsequent Events

The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form

-K.

Recent Accounting Pronouncements

February 2016,

the FASB established Topic

842,

Leases, by issuing Accounting Standards Update (ASU)

No.

2016

02,

which supersedes ASC

840,

Leases, and requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic

842

was subsequently amended by ASU

No.

2018

01,

Land Easement Practical Expedient for Transition to Topic

842;

ASU

No.

2018

10,

Codification Improvements to Topic

842,

Leases; and ASU

No.

2018

11,

Targeted Improvements. Topic

842,

as amended (the "new lease standard") establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than

months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The effective date of the new guidance is for the Company’s

first

quarter of fiscal year

2019.

The FASB has approved an optional, alternative method to adopt the lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the new standard effective

January 1, 2019,

using the alternative method. The Company does

not

have a cumulative adjustment impacting retained earnings. Adoption of the lease standard did

not

have a material impact on the Company’s consolidated financial statements.

June 2016,

the FASB issued ASU

No.

2016

13,

Financial Instruments—Credit Losses (Topic

326

): Measurement of Credit Losses on Financial Instruments. This ASU requires instruments measured at amortized cost to be presented at the net amount expected to be collected. Entities are also required to record allowances for available-for-sale debt securities rather than reduce the carrying amount. On

November 15, 2019,

the FASB delayed the effective date of the standard for certain small public companies and other private companies. As amended, the effective date of ASC Topic

326

was delayed until fiscal years beginning after

December 15, 2022

for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and

not

-for-profit entities. The Company expects that the adoption will

not

have a material impact on its consolidated financial statements.

December 2019,

the FASB issued ASU

No.

2019

12,

Income Taxes (Topic

740:

Simplifying the Accounting for Income Taxes

(“ASU

2019

12”

), which removes certain exceptions to the general principles in Topic

740.

ASU

2019

is effective for the fiscal years beginning after

December 15, 2020,

with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

Note 3 - Janssen Transaction	12 Months Ended
Note 3 - Janssen Transaction	Dec. 31, 2019
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	3. Janssen Transaction On December 7, 2019, the Company entered into an Asset Purchase Agreement with Janssen Biotech, Inc., under which Janssen acquired the Company’s True Human Antibody bermekimab to target interleukin- 1 alpha (IL- 1⍺ ) and the intellectual property associated with indications, particularly dermatological diseases. Upon closing, Janssen paid XBiotech $750 million, with $75 million held in an interest-bearing escrow account for 18 months to satisfy indemnity claims. There are no known asserted or unasserted claims with regard to the intellectual property as of December 31, 2019. In accordance with the agreement, ten Company employees from various departments were transferred to Janssen. Additionally, Janssen will pay the Company up to four milestone payments of $150 million each if it receives specified commercial authorizations within a specified timeframe for a pharmaceutical product that contains bermekimab and is for a non-dermatological indication. This represents contingent consideration; the Company has made a policy election not to recognize any amounts associated with these milestone payments upon execution of the arrangement and treat all amounts as a form of gain contingency. As no amount is currently reasonably certain of collection, these milestone payments were not included in the consideration in the contract. This transaction was accounted for as a sale of a business. The Company and Janssen also entered into an IP Non-Assertion and License Agreement, pursuant to which the Company granted Janssen a non-exclusive license to certain of its patents and intellectual property. Janssen granted the Company a non-exclusive license back of certain intellectual property rights and agreed not to assert certain claims from the patents acquired from the Company in the Janssen Transaction against the Company in connection with the Company’s new antibodies targeting IL- 1⍺ as described in the Purchase Agreement, to treat non-dermatological diseases. In addition, the Company entered into a Clinical Manufacturing Agreement, under which XBiotech USA agreed to manufacture bermekimab for use by Janssen in clinical trials, in exchange for fixed payments, paid in quarterly installments. Finally, The Company and Janssen entered into a Transition Services Agreement, under which XBiotech USA agreed to continue operational management, on a fee-for-service basis, of certain ongoing clinical trials related to bermekimab. As a result of Janssen Transaction, the Company recognized a gain of $750 million in non-operating income. Of the $750 million, $675 million was received and booked in cash and the remaining $75 million is held in an interest-bearing escrow account for 18 months and booked in long term assets as a receivable. In addition, the Company received a prepayment of $4.5 million from Janssen related to the clinical manufacturing agreement that will be performed in the first quarter in 2020, which the Company determined to be “at market” in exchange for the services in the clinical manufacturing agreement. The Company booked the $4.5 million within contract liabilities. Substantially all amounts transferred related to IPR&D, and as such, there was no carrying value of the amounts disposed in the Janssen Transaction. Additionally, the Company incurred approximately $572 thousand in expense due to professional fees. The Company determined the costs were “at market” and did not result in any additional consideration with respect to the sale. Income in the consolidated statement of cash flows includes the gain resulting from the Janssen Transaction. Net cash provided by operating activities related to Janssen Transaction was $4.5 million reflected within the operating cash inflow as a change in contract liabilities for the year ended December 31, 2019. Net cash provided by investing activities related to Janssen Transaction was $675 million for the year ended December 31, 2019.

Note 4 - Property and Equipment and Building Construction in Progress

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

Property and Equipment and Building Construction in Progress

Property and equipment consisted of the following as of

December

31,

2019

and

2018

(in thousands):

	2019			2018
Computer and office equipment	$	482		$	476
Furniture and fixtures		183			183
Land		1,418			1,418
Leasehold improvements		802			802
Scientific equipment		12,592			12,572
Vehicle		30			30
Building		21,013			21,013
Mobile facility		194			-
Construction in process		186			201
Accumulated depreciation		(11,729	)		(9,366	)
	$	25,171		$	27,329

Depreciation expenses related to property and equipment amounted to approximately

$2.4

million,

$2.4

million, and

$1.5

million for the years ended

December

31,

2019,

2018

and

2017,

respectively. Construction in process is related to research and development and manufactory equipment.

Note 5 - Accrued Expenses

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Expenses

Accrued expenses consist of the following as of

December

31,

2019,

and

2018

(in thousands):

	2019		2018
Accrued compensation and related expenses		337		258
Accrued professional fees		566		92
Accrued clinical trial expenses		3,082		905
Other		195		36
	$	4,180	$	1,291

Note 6 - Common Stock	12 Months Ended
Note 6 - Common Stock	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. Common Stock Pursuant to its Articles, the Company has an unlimited number of shares available for issuance with no par value. In February 2017, under the Common Stock Sales Agreement with H.C. Wainwright & Co. LLC, the Company sold 87 thousand shares of common stock at a price between $12.09 to $12.37 per share for total proceeds of $1.0 million. In March 2017, the Company sold 2.4 million shares of common stock at a net price of $13.00 for total proceeds of approximately $31.6 million from investors. From January through December 2017, 290 thousand shares of common stock were issued upon the exercise of stock options at a price of $2.50 to $14.71 per share for a total of $703 thousand. From January through December 2018, 161 thousand shares of common stock were issued upon the exercise of stock options at a price of $2.50 per share for a total of $401 thousand, of which $200 thousand is subscription receivable. During June 2019, under the Common Shares Purchase Agreement with Piper Jaffray & Co., the Company sold 4.8 million shares of common stock at a price $8.25 per share for total net proceeds of $37.5 million, including the capitalized underwriter’s commission of $2.3 million and other related fees of $0.2 million. From January through December 2019, 771 thousand shares of common stock were issued upon the exercise of stock options at a price of $2.50 to $15.00 per share for total proceeds of $3.8 million.

Note 7 - Common Stock Options

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

Common Stock Options

November 11, 2005,

the board of directors of the Company adopted the XBiotech Inc.

2005

Incentive Stock Option Plan (the

“2005

Plan”), and on

March 24, 2015,

the board of directors of the Company adopted the XBiotech Inc.

2015

Equity Incentive Plan (the

2015

Plan”) pursuant to which the Company

may

grant incentive stock and non-qualified stock options to directors, officers, employees or consultants of the Company or an affiliate or other persons as the Compensation Committee

may

approve.

All options under both Plans will be non-transferable and

may

be exercised only by the participant, or in the event of the death of the participant, a legal representative until the earlier of the options’ expiry date or the

first

anniversary of the participant’s death, or such other date as

may

be specified by the Compensation Committee.

The term of the options is at the discretion of the Compensation Committee, but

may

not

exceed

years from the grant date. The options expire on the earlier of the expiration date or the date

three

months following the day on which the participant ceases to be an officer or employee of or consultant to the Company, or in the event of the termination of the participant with cause, the date of such termination. Options held by non-employee Directors have an exercise period coterminous with the term of the options.

The number of common shares reserved for issuance to any

one

person pursuant to the

2005

Plan shall

not,

in aggregate, exceed

of the total number of outstanding common shares. The exercise price per common share under each option will be the fair market value of such shares at the time of the grant. Upon stock option exercise, the Company issues new shares of common stock.

A summary of changes in common stock options issued under the

2005

Plan and under the

2015

Plan is as follows:

	Options			Exercise Price			Weighted- Average Exercise Price
Options outstanding at December 31, 2016		5,188,658		$0.52	-	$21.99	$	8.49
Granted		1,251,000		4.15	-	12.6		4.85
Exercised		(406,667	)	0.93	-	14.71		2.28
Forfeitures		(729,367	)	0.94	-	21.99		11.90
Options outstanding at December 31, 2017		5,303,624		$2.50	-	$21.99	$	7.69
Granted		1,153,500		2.50	-	5.93		4.32
Exercised		(160,500	)		2.50			2.50
Forfeitures		(761,185	)	2.50	-	19.09		6.12
Options outstanding at December 31, 2018		5,535,439		$2.50	-	$21.99	$	7.30
Granted		2,563,500		5.15	-	19.87		9.36
Exercised		(771,376	)	2.5	-	15		4.62
Forfeitures		(361,833	)	2.50	-	16.50		7.53
Options outstanding at December 31, 2019		6,965,730		$2.71	-	$21.99		6.09

The weighted average fair value of the options issued to directors, employees and consultants during the fiscal years ended

December

31,

2019,

2018

and

2017,

was

$9.36,

$2.97

and

$2.97,

respectively. Options with an intrinsic value of $(

10.25

), $(

2.22

) and $(

3.75

), became vested during

2019,

2018

and

2017,

respectively. The total intrinsic value of options exercisable and total options outstanding at

December

31,

2019

and

December 31, 2018

was

$42.4

million and

$2.1

million respectively. The total fair value of options vested during the years ended

December

31,

2019,

2018

and

2017

was

$2.0

million,

$1.7

million, and

$1.6

million, respectively.

As of

December 31, 2019,

there was approximately

$16.5

million of unrecognized compensation cost, related to stock options granted under the Plan which will be amortized to stock compensation expense over the next

1.74

years.

Note 8 - Net Income (Loss) Per Share

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Earnings Per Share [Text Block]

Net Income/Loss Per Share

The following summarizes the computation of basic and diluted net income/loss per share for the years ended

December 31, 2019,

2018

and

2017

(in thousands, except share and per share data):

	Year Ended December 31,
	2019		2018			2017
Net income (loss)	$	668,629	$	(21,138	)	$	(33,150	)
Weighted-average number of common shares—basic		38,945,468		35,804,304			34,875,814
Net income (loss) per share—basic	$	17.17	$	(0.59	)	$	(0.95	)
Weighted-average number of common shares—diluted		46,319,457		35,804,304			34,875,814
Net income (loss) per share—diluted	$	14.44	$	(0.59	)	$	(0.95	)

The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average common shares outstanding, because including them would have had an anti-dilutive effect due to the losses reported.

	Year Ended December 31,
	2019		2018		2017
Stock options		6,965,730		5,535,439		5,303,624
Warrants to purchase common stock		-		-		-
Total		6,965,730		5,535,439		5,303,624

Note 9 - Income Taxes

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Income Tax Disclosure [Text Block]

Income Taxes

The components of income before income taxes are as follows:

(In thousands)	Years Ended December 31,
	2019			2018			2017
United States	$	53,971		$	(5,102	)	$	(5,765	)
Canada		664,689			(15,404	)		(26,034	)
Other Foreign		(207	)		(632	)		(1,351	)
Total	$	718,453		$	(21,138	)	$	(33,150	)

The components of the provision for income taxes are as follows for the years ended

December

31,

2019,

2018,

and

2017

(in thousands):

Current	2019			2018		2017
United States		1,806			-		-
Canada		48,031			-		-
Other Foreign		-			-		-
Total		49,837			-		-
Deferred
United States		-			-		-
Canada		(13	)		-		-
Other Foreign		-			-		-
Total		(13	)		-		-

Total income tax expense		49,824			-		-

The provision for income taxes differs from the amount computed by applying the Canada statutory rate to pre-tax income as follows for the years ended

December

31,

2019,

2018,

and

2017:

	2019			2018			2017
Income tax benefit computed at federal tax rate		27.0	%		26.0	%		26.0	%
Capital gain exclusion		(13.0	)%		-			-
Change in valuation allowance		(6.3	)%		(20.3	%)		(15.3	%)
Impacts of US tax reform		-			-			(13.4	%)
Prior year true-ups		(0.4	)%		(2.3	%)		-
Stock compensation and other		(0.4	)%		(3.4	)%		2.7	%
Total		6.9	%		—	%		—	%

December 22, 2017,

the President of the United States signed into law the Tax Cuts and Jobs Act, or TCJA, tax reform legislation. TJCA significantly changes U.S. tax law by, among other things, lowering U.S. corporate income tax rates and implementing a territorial tax system. TCJA reduced the U.S corporate tax rate from

35%

21%,

effective

January 1, 2018.

In connection with the initial analysis of the impact of TJCA, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally

21%.

The remeasurement of the Company’s’ deferred tax balance was offset by application of its valuation allowance. The Company applied the guidance in SAB

118

when accounting for the enactment-date effects of the Act in

2017

and throughout

2018.

During

2018,

the Company completed its

2017

income tax returns and its accounting for the enactment-date income tax effects of TCJA with

adjustments to the provisional amounts recorded at

December 31, 2017.

Significant components of the Company’s deferred tax assets and liabilities as of

December

31,

2019,

2018,

and

2017

as follows (in thousands):

	2019			2018			2017
Deferred tax assets:
Noncapital losses	$	43		$	43,474		$	41,551
Qualifying research and development credits		-			3,119			2,833
Stock based compensation		2,354			1,712			1,618
Share issue costs		587			128			42
Accrued liabilities		699			229			49
Deferred rent		-			1			4

Total deferred tax assets		3,683			48,663			46,097

Deferred tax liabilities:
Depreciation		348			166			282
Prepaid assets		98			55			-
Share issuance costs		-			-			35
Total deferred tax liabilities		446			221			317
Net deferred tax asset		3,237			48,442			45,780
Valuation allowance for deferred tax assets		(2,794	)		(48,442	)		(45,780	)
Net deferred tax asset including valuation allowance	$	443		$	—		$	—

As of

December 31, 2019,

and

2018,

the Company had unused net operating losses of approximately

$0.1

million in Switzerland and Japan, and approximately

$173.2

million (

$141.7

million in Canada,

$30.9

million in the U.S., and

$0.6

million in Switzerland and Japan), respectively, available to reduce taxable income of future years. The tax benefit of net operating losses begins to expire in

2022

in Switzerland and Japan.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. With the exception of certain items as of

December 31, 2019

that will generate cash refunds through loss carryback claims in the next

three

years, the Company has established a full valuation allowance in the U.S., Switzerland, Japan and a partial valuation allowance on certain deferred tax assets in Canada due to uncertainties regarding the realization of these deferred tax assets based upon the Company’s lack of earnings history and the Company expects to continue to incur significant expenses for the foreseeable future.

We have

not

provided Canadian income taxes and withholding taxes on the undistributed earnings of U.S. subsidiary as of

December 31, 2019,

because we intend to indefinitely reinvest such earnings. We intend to use available cash to expand our research and development and manufacturing facilities and also fund the development of our manufacturing processes.

Due to the usage of substantially all net operating losses and tax credit carryforwards as a result of the Janssen Transaction, the valuation allowance decreased by

$45.6

million during the year ended

December 31, 2019.

The valuation allowance increased by

$2.6

million during the year ended

December 31, 2018

due to additional losses incurred during the year.

The Company applies the accounting guidance in ASC

740

related to accounting for uncertainty in income taxes. The Company’s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the Company in its tax filings or positions is more likely than

not

to be realized following resolution of any potential contingencies present related to the tax benefit. A reconciliation of the beginning and ending amount of unrecognized tax benefits as of

December

31,

2019,

2018

and

2017

is as follows (in thousands):

	2019		2018		2017
Balance as of January 1		0		0		0
Additions based on tax positions related to the current year		46		0		0
Additions for tax positions of prior years		1,010		0		0
Reductions for tax positions of prior years		0		0		0
Settlements		0		0		0
Balance at December 31		1,056		-		-

interest or penalties were recognized or accrued as of

December 31, 2019,

2018,

and

2017.

As of

December 31, 2019,

2018,

and

2017,

there are

$1.1

million,

million, and

million of unrecognized tax benefits that if recognized would affect the annual effective tax rate.

The Company files federal income tax returns in Canada, U.S, Switzerland, Germany, and Japan. The Company also files income tax returns in the state of Texas in the U.S. The statute of limitations for assessment by local taxing authorities is open for tax years ended after

December 2012

and all years since

2008

for the U.S. remain open until such time the

2019

tax year statute of limitation closes. There are currently

federal or state income tax audits in progress.

Note 10 - Subsequent Event	12 Months Ended
Note 10 - Subsequent Event	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	10. Subsequent Event The Company commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares on January 14, 2020. The Company announced the final results of the tender offer on February 19, 2020. Based on the final count by American Stock Transfer & Trust Co., LLC, the depositary for the tender offer, a total of 40,007,286 common shares, no par value, were properly tendered and not properly withdrawn at or below the maximum purchase price of $33.00 per share. The Company has accepted for purchase 14,000,000 common shares at a price of $30.00 per share, for an aggregate cost of approximately $420 million, excluding fees and expenses relating to the tender offer. These shares represented approximately 32.67 percent of the common shares outstanding. The final proration factor for shares that XBiotech purchased pursuant to the tender offer was approximately 33.25 percent.

Note 11 - Selected Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Quarterly Financial Information [Text Block]

11.

Selected Quarterly Financial Data (Unaudited)

Selected Quarterly Financial Data (Unaudited) for the year ended

December 31, 2019

and

2018

is presented below (in thousands except per share data):

2019	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Loss from operations		(5,805	)		(6,006	)		(6,111	)		(13,311	)
Net income (loss)		(5,864	)		(5,852	)		(6,150	)		686,495
Net income (loss) per share—basic		(0.16	)		(0.16	)		(0.15	)		16.67
Net income (loss) per share—diluted		(0.16	)		(0.16	)		(0.15	)		14.82

2018	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Loss from operations		(4,150	)		(5,621	)		(5,115	)		(6,108	)
Net Loss		(4,069	)		(5,907	)		(5,051	)		(6,111	)
Net loss per share—basic and diluted		(0.11	)		(0.16	)		(0.14	)		(0.17	)

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (US GAAP).

Consolidation, Policy [Policy Text Block]

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Prior to its initial public offering on

April 15, 2015,

third

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

alternative future use are expensed as incurred as research and development costs.

Income Tax, Policy [Policy Text Block]

Income Taxes

may

in the future determine that certain deferred tax assets more-likely-than-

not

be realized, in which case the Company will reduce its valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, the Company

may

recognize a benefit from income taxes in its statement of operations in that period.

Income taxes are recorded in accordance with ASC

740,

Accounting for Income Taxes

(“ASC

740”

not

that some or all of the deferred tax assets will

not

be realized.

ASC

740

clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position

may

be recognized when it is more likely than

not

Share-based Payment Arrangement [Policy Text Block]

Share-Based Compensation

The Company accounts for its share-based compensation awards in accordance with ASC Topic

718,

Compensation-Stock Compensation

(“ASC

718”

). ASC

718,

Share-based compensation expense recognized for the years ended

December 31, 2019,

2018

and

2017

was included in the following line items on the Consolidated Statements of Operations (in thousands).

	Year Ended December 31,
	2019		2018		2017

Research and development	$	1,635	$	696	$	413
General and administrative		1,723		964		2,063

Total share-based compensation expense	$	3,358	$	1,660	$	2,476

The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions:

	Year Ended December 31,
	2019			2018			2017
Weighted-average grant date fair value per share		$9.36			$4.32			$4.85
Expected volatility	80%	-	97%	67%	-	80%	65%	-	67%
Risk-free interest rate	1.41%	-	2.64%	2.38%	-	3.12%	1.83%	-	2.41%
Expected life (in years)	5.38	–	10	1	–	10	5.38	–	10
Dividend yield		—			—			—

Due to the adoption of ASU

No.

2016

09,

“Stock Compensation” on

January 1, 2017,

the Company accounts for forfeitures as they occur rather than on an estimated basis.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company considers highly liquid investments with a maturity of

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations of Credit Risk

one

financial institution. These amounts at times

may

exceed federally insured limits. The Company has

not

experienced any credit losses in such accounts and does

not

believe it is exposed to any significant credit risk on these funds. The Company has

off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

The Company follows ASC Topic

820,

Fair Value Measurements and Disclosures

three

levels:

	•	Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities.

	•	Level 2—Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

•

Level

3—Unobservable

December 31, 2019

and

2018,

the Company did

not

December 31, 2019

and

2018,

due to their short-term nature.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

not

depreciated, using the straight line method. The useful lives are as follows:

• Furniture and fixtures	7 years

• Office equipment	5 years

• Scientific equipment	5 years

• Vehicles	5 years

• Mobile facility	27.5 years

• Building	39 years

Costs of major additions and betterments are capitalized; maintenance and repairs, which do

not

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic

360,

Property, Plant and Equipment

. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset

may

not

recognized any impairment through

December 31, 2019.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Transactions

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income (Loss)

ASC Topic

220,

Comprehensive Income

Segment Reporting, Policy [Policy Text Block]

Segment and Geographic Information

one

operating segment. Substantially all of the Company’s operations are in the U.S. geographic segment.

Earnings Per Share, Policy [Policy Text Block]

Net Income/Loss per Share

Subsequent Events, Policy [Policy Text Block]

Subsequent Events

-K.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

February 2016,

the FASB established Topic

842,

Leases, by issuing Accounting Standards Update (ASU)

No.

2016

02,

which supersedes ASC

840,

Leases, and requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic

842

was subsequently amended by ASU

No.

2018

01,

Land Easement Practical Expedient for Transition to Topic

842;

ASU

No.

2018

10,

Codification Improvements to Topic

842,

Leases; and ASU

No.

2018

11,

Targeted Improvements. Topic

842,

first

quarter of fiscal year

2019.

January 1, 2019,

using the alternative method. The Company does

not

have a cumulative adjustment impacting retained earnings. Adoption of the lease standard did

not

have a material impact on the Company’s consolidated financial statements.

June 2016,

the FASB issued ASU

No.

2016

13,

Financial Instruments—Credit Losses (Topic

326

November 15, 2019,

the FASB delayed the effective date of the standard for certain small public companies and other private companies. As amended, the effective date of ASC Topic

326

was delayed until fiscal years beginning after

December 15, 2022

for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and

not

-for-profit entities. The Company expects that the adoption will

not

have a material impact on its consolidated financial statements.

December 2019,

the FASB issued ASU

No.

2019

12,

Income Taxes (Topic

740:

Simplifying the Accounting for Income Taxes

(“ASU

2019

12”

), which removes certain exceptions to the general principles in Topic

740.

ASU

2019

is effective for the fiscal years beginning after

December 15, 2020,

with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

Note 2 - Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Year Ended December 31,
	2019		2018		2017

Research and development	$	1,635	$	696	$	413
General and administrative		1,723		964		2,063

Total share-based compensation expense	$	3,358	$	1,660	$	2,476

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Year Ended December 31,
	2019			2018			2017
Weighted-average grant date fair value per share		$9.36			$4.32			$4.85
Expected volatility	80%	-	97%	67%	-	80%	65%	-	67%
Risk-free interest rate	1.41%	-	2.64%	2.38%	-	3.12%	1.83%	-	2.41%
Expected life (in years)	5.38	–	10	1	–	10	5.38	–	10
Dividend yield		—			—			—

Note 4 - Property and Equipment and Building Construction in Progress (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Property, Plant and Equipment [Table Text Block]

	2019			2018
Computer and office equipment	$	482		$	476
Furniture and fixtures		183			183
Land		1,418			1,418
Leasehold improvements		802			802
Scientific equipment		12,592			12,572
Vehicle		30			30
Building		21,013			21,013
Mobile facility		194			-
Construction in process		186			201
Accumulated depreciation		(11,729	)		(9,366	)
	$	25,171		$	27,329

Note 5 - Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	2019		2018
Accrued compensation and related expenses		337		258
Accrued professional fees		566		92
Accrued clinical trial expenses		3,082		905
Other		195		36
	$	4,180	$	1,291

Note 7 - Common Stock Options (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Options			Exercise Price			Weighted- Average Exercise Price
Options outstanding at December 31, 2016		5,188,658		$0.52	-	$21.99	$	8.49
Granted		1,251,000		4.15	-	12.6		4.85
Exercised		(406,667	)	0.93	-	14.71		2.28
Forfeitures		(729,367	)	0.94	-	21.99		11.90
Options outstanding at December 31, 2017		5,303,624		$2.50	-	$21.99	$	7.69
Granted		1,153,500		2.50	-	5.93		4.32
Exercised		(160,500	)		2.50			2.50
Forfeitures		(761,185	)	2.50	-	19.09		6.12
Options outstanding at December 31, 2018		5,535,439		$2.50	-	$21.99	$	7.30
Granted		2,563,500		5.15	-	19.87		9.36
Exercised		(771,376	)	2.5	-	15		4.62
Forfeitures		(361,833	)	2.50	-	16.50		7.53
Options outstanding at December 31, 2019		6,965,730		$2.71	-	$21.99		6.09

Note 8 - Net Income (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year Ended December 31,
	2019		2018			2017
Net income (loss)	$	668,629	$	(21,138	)	$	(33,150	)
Weighted-average number of common shares—basic		38,945,468		35,804,304			34,875,814
Net income (loss) per share—basic	$	17.17	$	(0.59	)	$	(0.95	)
Weighted-average number of common shares—diluted		46,319,457		35,804,304			34,875,814
Net income (loss) per share—diluted	$	14.44	$	(0.59	)	$	(0.95	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Year Ended December 31,
	2019		2018		2017
Stock options		6,965,730		5,535,439		5,303,624
Warrants to purchase common stock		-		-		-
Total		6,965,730		5,535,439		5,303,624

Note 9 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

(In thousands)	Years Ended December 31,
	2019			2018			2017
United States	$	53,971		$	(5,102	)	$	(5,765	)
Canada		664,689			(15,404	)		(26,034	)
Other Foreign		(207	)		(632	)		(1,351	)
Total	$	718,453		$	(21,138	)	$	(33,150	)

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

Current	2019			2018		2017
United States		1,806			-		-
Canada		48,031			-		-
Other Foreign		-			-		-
Total		49,837			-		-
Deferred
United States		-			-		-
Canada		(13	)		-		-
Other Foreign		-			-		-
Total		(13	)		-		-

Total income tax expense		49,824			-		-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2019			2018			2017
Income tax benefit computed at federal tax rate		27.0	%		26.0	%		26.0	%
Capital gain exclusion		(13.0	)%		-			-
Change in valuation allowance		(6.3	)%		(20.3	%)		(15.3	%)
Impacts of US tax reform		-			-			(13.4	%)
Prior year true-ups		(0.4	)%		(2.3	%)		-
Stock compensation and other		(0.4	)%		(3.4	)%		2.7	%
Total		6.9	%		—	%		—	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	2019			2018			2017
Deferred tax assets:
Noncapital losses	$	43		$	43,474		$	41,551
Qualifying research and development credits		-			3,119			2,833
Stock based compensation		2,354			1,712			1,618
Share issue costs		587			128			42
Accrued liabilities		699			229			49
Deferred rent		-			1			4

Total deferred tax assets		3,683			48,663			46,097

Deferred tax liabilities:
Depreciation		348			166			282
Prepaid assets		98			55			-
Share issuance costs		-			-			35
Total deferred tax liabilities		446			221			317
Net deferred tax asset		3,237			48,442			45,780
Valuation allowance for deferred tax assets		(2,794	)		(48,442	)		(45,780	)
Net deferred tax asset including valuation allowance	$	443		$	—		$	—

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	2019		2018		2017
Balance as of January 1		0		0		0
Additions based on tax positions related to the current year		46		0		0
Additions for tax positions of prior years		1,010		0		0
Reductions for tax positions of prior years		0		0		0
Settlements		0		0		0
Balance at December 31		1,056		-		-

Note 11 - Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Quarterly Financial Information [Table Text Block]

2019	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Loss from operations		(5,805	)		(6,006	)		(6,111	)		(13,311	)
Net income (loss)		(5,864	)		(5,852	)		(6,150	)		686,495
Net income (loss) per share—basic		(0.16	)		(0.16	)		(0.15	)		16.67
Net income (loss) per share—diluted		(0.16	)		(0.16	)		(0.15	)		14.82

2018	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Loss from operations		(4,150	)		(5,621	)		(5,115	)		(6,108	)
Net Loss		(4,069	)		(5,907	)		(5,051	)		(6,111	)
Net loss per share—basic and diluted		(0.11	)		(0.16	)		(0.14	)		(0.17	)

Note 1 - Organization (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 714,594	$ 15,823	$ 31,768	$ 34,324

Note 2 - Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)	Jan. 01, 2019 USD ($)	Dec. 31, 2018 USD ($)
Impairment of Long-Lived Assets Held-for-use	$ 0
Number of Operating Segments	1
Accounting Standards Update 2016-02 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		$ 0
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Office Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member]
Property, Plant and Equipment, Useful Life	5 years
Mobile Facility [Member]
Property, Plant and Equipment, Useful Life	27 years 182 days
Building [Member]
Property, Plant and Equipment, Useful Life	39 years
Fair Value, Recurring [Member]
Assets, Fair Value Disclosure	$ 0		$ 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0		$ 0

Note 2 - Significant Accounting Policies - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based compensation expense	$ 3,358	$ 1,660	$ 2,476
Research and Development Expense [Member]
Share-based compensation expense	1,635	696	413
General and Administrative Expense [Member]
Share-based compensation expense	$ 1,723	$ 964	$ 2,063

Note 2 - Significant Accounting Policies - Stock Option Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Weighted-average grant date fair value per share (in dollars per share)	$ 9.36	$ 4.32	$ 4.85
Dividend yield
Minimum [Member]
Expected volatility	80.00%	67.00%	65.00%
Risk-free interest rate	1.41%	2.38%	1.83%
Expected life (Year)	5 years 138 days	1 year	5 years 138 days
Maximum [Member]
Expected volatility	97.00%	80.00%	67.00%
Risk-free interest rate	2.64%	3.12%	2.41%
Expected life (Year)	10 years	10 years	10 years

Note 3 - Janssen Transaction (Details Textual) $ in Thousands		12 Months Ended
	Dec. 07, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal		$ 750,000
Amount Held in Escrow		(75,000)
Proceeds from Sale of Productive Assets, Total		675,000
True Human Antibody Bermekimab [Member]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	$ 750,000
Amount Held in Escrow	$ 75,000
Period of Amount Held in Escrow	1 year 180 days
Milestone Payments to be Received, Number of Installments	4
Milestone Payments to be Received for each Installment	$ 150,000
Proceeds from Sale of Productive Assets, Total	675,000	675,000
Prepaid Expense, Current, Total	4,500
Professional Fees	$ 572
Proceeds from Sale of Productive Assets, Operating Activities		$ 4,500

Note 4 - Property and Equipment and Building Construction in Progress (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 2,361	$ 2,433	$ 1,484

Note 4 - Property and Equipment and Building Construction in Progress - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accumulated depreciation	$ (11,729)	$ (9,366)
	25,171	27,329
Office Equipment [Member]
Property, plant, and equipment, gross	482	476
Furniture and Fixtures [Member]
Property, plant, and equipment, gross	183	183
Land [Member]
Property, plant, and equipment, gross	1,418	1,418
Leasehold Improvements [Member]
Property, plant, and equipment, gross	802	802
Scientific Equipment [Member]
Property, plant, and equipment, gross	12,592	12,572
Vehicles [Member]
Property, plant, and equipment, gross	30	30
Building [Member]
Property, plant, and equipment, gross	21,013	21,013
Mobile Facility [Member]
Property, plant, and equipment, gross	194
Construction in Progress [Member]
Property, plant, and equipment, gross	$ 186	$ 201

Note 5 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued compensation and related expenses	$ 337	$ 258
Accrued professional fees	566	92
Accrued clinical trial expenses	3,082	905
Other	195	36
	$ 4,180	$ 1,291

Note 6 - Common Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			12 Months Ended
	Jun. 30, 2019	Mar. 31, 2017	Feb. 28, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Common Stock, No Par Value				$ 0	$ 0
Stock Issued During Period, Shares, New Issues		2,400,000	87,000
Shares Issued, Price Per Share		$ 13
Proceeds from Issuance of Common Stock		$ 31,600	$ 1,000	$ 3,800		$ 703
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				771,376	160,500	406,667
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price					$ 2.50
Proceeds from Stock Options Exercised					$ 401
Stockholders' Equity Note, Subscriptions Receivable					$ 200
Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues	4,800,000
Shares Issued, Price Per Share	$ 8.25
Proceeds from Issuance of Common Stock, Net	$ 37,500
Underwriter's Commission Attributable to Issuance of Common Stock	2,300
Other Related Fee Attributable to Issuance of Common Stock	$ 200
Minimum [Member]
Shares Issued, Price Per Share			$ 12.09	2.50		$ 2.50
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				2.50		0.93
Maximum [Member]
Shares Issued, Price Per Share			$ 12.37	15		14.71
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				$ 15		$ 14.71

Note 7 - Common Stock Options (Details Textual) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 9.36	$ 4.32	$ 4.85
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 16.5
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	1 year 270 days
The Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 9.36	2.97	2.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Intrinsic Value, Amount Per Share	$ 10.25	$ 2.22	$ 3.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 42.4	$ 2.1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 2.0	$ 1.7	$ 1.6
The Plan [Member] \| Any One Person [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	5.00%
The Plan [Member] \| Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years

Note 7 - Common Stock Options - Changes in Common Stock Options Issued (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Options outstanding (in shares)	5,535,439	5,303,624	5,188,658
Granted (in shares)	2,563,500	1,153,500	1,251,000
Granted, exercise price (in dollars per share)
Exercised (in shares)	(771,376)	(160,500)	(406,667)
Exercised, exercise price (in dollars per share)		$ 2.50
Forfeitures (in shares)	(361,833)	(761,185)	(729,367)
Options outstanding (in shares)	6,965,730	5,535,439	5,303,624
Minimum [Member]
Options outstanding, exercise price (in dollars per share)	$ 2.50	$ 2.50	$ 0.52
Granted, exercise price (in dollars per share)	5.15	2.50	4.15
Exercised, exercise price (in dollars per share)	2.50		0.93
Forfeitures, exercise price (in dollars per share)	2.50	2.50	0.94
Options outstanding, exercise price (in dollars per share)	2.71	2.50	2.50
Maximum [Member]
Options outstanding, exercise price (in dollars per share)	21.99	21.99	21.99
Granted, exercise price (in dollars per share)	19.87	5.93	12.60
Exercised, exercise price (in dollars per share)	15		14.71
Forfeitures, exercise price (in dollars per share)	16.50	19.09	21.99
Options outstanding, exercise price (in dollars per share)	21.99	21.99	21.99
Weighted Average [Member]
Options outstanding, exercise price (in dollars per share)	7.30	7.69	8.49
Granted, exercise price (in dollars per share)	9.36	4.32	4.85
Exercised, exercise price (in dollars per share)	4.62	2.50	2.28
Forfeitures, exercise price (in dollars per share)	7.53	6.12	11.90
Options outstanding, exercise price (in dollars per share)	$ 6.09	$ 7.30	$ 7.69

Note 8 - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net income (loss)	$ 686,495	$ (6,150)	$ (5,852)	$ (5,864)	$ (6,111)	$ (5,051)	$ (5,907)	$ (4,069)	$ 668,629	$ (21,138)	$ (33,150)
Weighted-average number of common shares—basic (in shares)									38,945,468	35,804,304	34,875,814
Net income (loss) per share—basic (in dollars per share)	$ 16.67	$ (0.15)	$ (0.16)	$ (0.16)					$ 17.17	$ (0.59)	$ (0.95)
Weighted-average number of common shares—diluted (in shares)									46,319,457	35,804,304	34,875,814
Net income (loss) per share—diluted (in dollars per share)	$ 14.82	$ (0.15)	$ (0.16)	$ (0.16)					$ 14.44	$ (0.59)	$ (0.95)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 8 - Net Income (Loss) Per Share - Potentially Dilutive Securities Outstanding (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive securities (in shares)	6,965,730	5,535,439	5,303,624
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	6,965,730	5,535,439	5,303,624
Warrant [Member]
Antidilutive securities (in shares)

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards, Total		$ 173,200
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (45,600)	2,600
Unrecognized Tax Benefits, Ending Balance	1,056	0	$ 0	$ 0
Income Tax Examination, Penalties and Interest Expense, Total	0	0	$ 0
Foreign Tax Authority [Member] \| Swiss Federal Tax Administration (FTA) and National Tax Agency, Japan [Member]
Operating Loss Carryforwards, Total	$ 100	600
Foreign Tax Authority [Member] \| Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total		30,900
Domestic Tax Authority [Member] \| Canada Revenue Agency [Member]
Operating Loss Carryforwards, Total		$ 141,700

Note 9 - Income Taxes - Components of Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Canada	$ 664,689	$ (15,404)	$ (26,034)
Total	718,453	(21,138)	(33,150)
UNITED STATES
United States	53,971	(5,102)	(5,765)
Other Foreign [Member]
United States	$ (207)	$ (632)	$ (1,351)

Note 9 - Income Taxes - Income Tax from Continuing Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
United States	$ 1,806
Canada	48,031
Other Foreign
Total	49,837
United States
Canada	(13)
Other Foreign
Total	(13)
Total income tax expense	$ 49,824

Note 9 - Income Taxes - Reconciliation of Canadian Federal Statutory Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income tax benefit computed at federal tax rate	27.00%	26.00%	26.00%
Capital gain exclusion	(13.00%)
Change in valuation allowance	(6.30%)	(20.30%)	(15.30%)
Impacts of US tax reform			(13.40%)
Prior year true-ups	(0.40%)	(2.30%)
Stock compensation and other	(0.40%)	(3.40%)	2.70%
Total	6.90%

Note 9 - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Noncapital losses	$ 43	$ 43,474	$ 41,551
Qualifying research and development credits		3,119	2,833
Stock based compensation	2,354	1,712	1,618
Share issue costs	587	128	42
Accrued liabilities	699	229	49
Deferred rent		1	4
Total deferred tax assets	3,683	48,663	46,097
Deferred tax liabilities:
Depreciation	348	166	282
Prepaid assets	98	55
Share issuance costs			35
Total deferred tax liabilities	446	221	317
Net deferred tax asset	3,237	48,442	45,780
Valuation allowance for deferred tax assets	(2,794)	(48,442)	(45,780)
Net deferred tax asset including valuation allowance	$ 443

Note 9 - Income Taxes - Reconciliation of Unrecognized Tax Benefit Balances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Balance	$ 0	$ 0	$ 0
Additions based on tax positions related to the current year	46	0	0
Additions for tax positions of prior years	1,010	0	0
Reductions for tax positions of prior years	0	0	0
Settlements	0	0	0
Balance	$ 1,056	$ 0	$ 0

Note 10 - Subsequent Event (Details Textual) - USD ($)	Feb. 19, 2020	Dec. 31, 2019	Dec. 31, 2018
Common Stock, No Par Value		$ 0	$ 0
Subsequent Event [Member]
Stock Repurchase Program, Authorized Amount	$ 420,000,000
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	40,007,286
Common Stock, No Par Value	$ 0
Stock Repurchased During Period, Shares	14,000,000
Stock Repurchased During Period, Price Per Share	$ 30
Stock Repurchased During Period, Value	$ 420,000,000
Percentage of Outstanding Shares Repurchased	32.67%
Percentage of Outstanding Shares to be Repurchased	33.25%
Subsequent Event [Member] \| Maximum [Member]
Stock Repurchase Program, Maximum Purchase Price Per Share	$ 33

Note 11 - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Loss from operations	$ (13,311)	$ (6,111)	$ (6,006)	$ (5,805)	$ (6,108)	$ (5,115)	$ (5,621)	$ (4,150)	$ (31,233)	$ (20,994)	$ (34,059)
Net income (loss)	$ 686,495	$ (6,150)	$ (5,852)	$ (5,864)	$ (6,111)	$ (5,051)	$ (5,907)	$ (4,069)	$ 668,629	$ (21,138)	$ (33,150)
Net income (loss) per share—basic (in dollars per share)	$ 16.67	$ (0.15)	$ (0.16)	$ (0.16)					$ 17.17	$ (0.59)	$ (0.95)
Net income (loss) per share—diluted (in dollars per share)	$ 14.82	$ (0.15)	$ (0.16)	$ (0.16)					$ 14.44	$ (0.59)	$ (0.95)
Net loss per share—basic and diluted (in dollars per share)					$ (0.17)	$ (0.14)	$ (0.16)	$ (0.11)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details